TP53 and neoplasm: This results in an increase in the intracellular levels of p53 as well as its DNA-binding activity and elevates the cyclin-dependent kinase inhibitors, p21 and p27, thereby inducing cancer cell cycle arrest at G2/M and tumor growth inhibition [64,66].